Table 2.
Course of laboratory tests over time in patient 2
| Days from admission at Authors’ center | -4 | 0 | + 20 | + 30 | + 35a | + 40 | + 50 |
|---|---|---|---|---|---|---|---|
| White blood cells (×103/mm3) | 14.2 | 10.6 | 3.4 | 5.4 | 3.7 | 18.9 | 5.5 |
| Neutrophil count (× 103/mm3) | 11.9 | 6.6 | 1.9 | 3.4 | 1.7 | 15.1 | 2.9 |
| Hemoglobin (g/dL) | 9.2 | 11.2 | 10.8 | 10.8 | 10.5 | 9.9 | 11.1 |
| Platelet count (×103/mm3) | 285 | 424 | 105 | 233 | 145 | 164 | 253 |
| Erythrocyte sedimentation rate (mm/h) | 75 | 68 | 43 | 55 | 63 | 50 | 36 |
| C-reactive protein (mg/dL) | 2.5 | < 0.46 | 1.83 | < 0.46 | 0.6 | < 0.46 | < 0.46 |
| Aspartate aminotransferase (U/L) | 61 | 40 | 350 | 111 | 113 | 35 | 31 |
| Lactate dehydrogenase (U/L) | 1673 | 1048 | 4960 | 1541 | 2122 | 1116 | 468 |
| Triglycerides (mg/dL) | 209 | 173 | 273 | – | 157 | – | – |
| Fibrinogen (mg/dL) | 356 | 418 | 234 | 297 | 424 | 312 | 267 |
| Ferritin (ng/mL) | 20,350 | 5065 | 49,700 | 17,580 | 28,634 | 12,340 | 201 |
aStart of canakinumab administration